Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Turmeric compound tested as sepsis treatment in new trial

NCT ID NCT07436130

Disease control Sponsor: Hospital Civil de Guadalajara Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 18, 2026 · Updated 3 times

Summary

This study tests whether curcumin, the active compound in turmeric, can help regulate the overactive immune response in critically ill patients with sepsis. Fifty-six participants will receive either curcumin or a placebo alongside standard care for 10 days. Researchers will measure changes in inflammatory markers in the blood to see if curcumin can reduce harmful inflammation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
curcumin (a natural compound from turmeric)
What this could lead to
If it works, curcumin could become a low-cost addition to standard sepsis care, helping to control harmful inflammation and potentially improving recovery.
What could go wrong
This is a small, early-stage trial (56 people) testing only a blood marker, not survival or major outcomes. Curcumin may show no benefit or could interact with other treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 56 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients older than 18 years of either sex. * Critically ill patients with a diagnosis of sepsis admitted to the Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde." * Patients receiving enteral nutrition. * Written informed consent signed by the patient or their legally authorized representative. Exclusion Criteria: * Patients with a history of allergy or hypersensitivity to curcumin. * Patients with autoimmune diseases or severe immunosuppression. * Patients in a terminal condition with a life expectancy of less than 48 hours. * Patients with intolerance to enteral feeding, intestinal ischemia, intestinal obstruction, pancreatitis or short bowel syndrome. * Patients with acute liver failure or decompensated liver cirrhosis. * Patients with clinically significant active bleeding (e.g., gastrointestinal bleeding, intracranial hemorrhage, etc.). * Patients requiring therapeutic anticoagulation (warfarin, direct oral anticoagulants \[DOACs\], or full-dose heparin). * Patients receiving exclusively parenteral nutrition. * Pregnant or breastfeeding women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sepsis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Critical Illness infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sepsis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde"

    RECRUITING

    Guadalajara, Jalisco, 44280, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.